Compare WM & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WM | BDX |
|---|---|---|
| Founded | 1968 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.1B | 40.3B |
| IPO Year | 2002 | 1997 |
| Metric | WM | BDX |
|---|---|---|
| Price | $215.69 | $141.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $255.89 | $186.00 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | 1.64% | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | 0.25 |
| Revenue | $14,485,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | $5.45 | $3.02 |
| P/E Ratio | ★ $122.13 | $579.88 |
| Revenue Growth | 6.44 | ★ 8.24 |
| 52 Week Low | $194.11 | $141.82 |
| 52 Week High | $248.13 | $213.08 |
| Indicator | WM | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 36.96 |
| Support Level | $212.82 | N/A |
| Resistance Level | $221.01 | $153.09 |
| Average True Range (ATR) | 4.26 | 3.11 |
| MACD | 0.31 | -0.35 |
| Stochastic Oscillator | 34.35 | 5.55 |
WM, previously known as Waste Management, ranks as the largest integrated provider of traditional solid waste services in the United States, operating 257 active landfill sites and about 342 transfer stations that help with transporting waste efficiently and economically. The company serves residential, commercial, industrial, and medical end markets for waste collection, transfer, and disposal. The company also has an energy business emanating from the beneficial use of landfill gas and is a leading recycler in North America.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.